BTIG Maintains Buy on MDxHealth, Lowers Price Target to $2
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.